Psoriatic Arthritis
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.
Feature
Psoriatic disease: Researchers seek a PsA diagnostic test, phenotype-targeted treatment
Researchers described ongoing work to “understand the discrete and overlapping endotypes that underlie the phenotypes” of psoriatic disease and to...
Latest News
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
With this approval, bimekizumab becomes the only interleukin (IL)-17A and IL-17F inhibitor approved for the treatment of these patients.
Latest News
Pilot study: High-dose IL-23 inhibition shows promise for psoriasis remission in some patients
Targeting resident memory T cells may be a key to long-term remission.
News from the FDA/CDC
Approximately 20% of U.S. adults are diagnosed with arthritis
New data show disproportionate arthritis prevalence among women, veterans, non-Hispanic White individuals, and those aged 45 years and older.
Latest News
Roflumilast side effect benefits patients with psoriasis and overweight/obesity
An “extraordinary” finding was how some patients’ weight status based on their BMI changed throughout the study.
Latest News
Pediatric psoriasis: Black children, males more likely to have palmoplantar subtype, study finds
Nail involvement occurred in significantly more Black and Hispanic/Latino patients than in White patients.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
Latest News
Choosing which biologic to prescribe for psoriasis
In cases of primary failure, consider revisiting the diagnosis, Dr. April Armstrong advised.
Latest News
FDA approves topical roflumilast for psoriasis in children aged 6-11
Topical roflumilast was first approved in July 2022 for individuals aged 12 and older.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...